Blau Farmacêutica S.A.

BOVESPA:BLAU3 Stock Report

Market Cap: R$2.5b

Blau Farmacêutica Future Growth

Future criteria checks 1/6

Blau Farmacêutica is forecast to grow earnings and revenue by 8.6% and 10.8% per annum respectively. EPS is expected to grow by 8.6% per annum. Return on equity is forecast to be 13.7% in 3 years.

Key information

8.6%

Earnings growth rate

8.61%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate10.8%
Future return on equity13.68%
Analyst coverage

Good

Last updated07 May 2025

Recent future growth updates

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07
Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

author-image

Latin America Expansion And R&D Will Unlock New Markets

Strategic LatAm expansion and international partnerships are set to boost revenue and expand market share across multiple countries.

Blau Farmacêutica (BVMF:BLAU3) Has A Pretty Healthy Balance Sheet

Mar 21
Blau Farmacêutica (BVMF:BLAU3) Has A Pretty Healthy Balance Sheet

Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Dec 04
Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07
Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Nov 06
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28
Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01
Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Earnings and Revenue Growth Forecasts

BOVESPA:BLAU3 - Analysts future estimates and past financials data (BRL Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,418346673796
12/31/20262,179309433246
12/31/20252,006305222951
3/31/20251,768268162447N/A
12/31/20241,754217223507N/A
9/30/20241,68618588333N/A
6/30/20241,5752142238N/A
3/31/20241,47423820284N/A
12/31/20231,373250-44221N/A
9/30/20231,352317-7253N/A
6/30/20231,3513128262N/A
3/31/20231,35235433229N/A
12/31/20221,407363-8172N/A
9/30/20221,390314104267N/A
6/30/20221,34831396252N/A
3/31/20221,354301-21137N/A
12/31/20211,366325-24154N/A
9/30/20211,3543549166N/A
6/30/20211,338335-13146N/A
3/31/20211,28930913208N/A
12/31/20201,18225453224N/A
9/30/20201,066238-17183N/A
6/30/20201,02921476245N/A
3/31/20201,008203103217N/A
12/31/2019978200125221N/A
9/30/201998718672131N/A
6/30/20199381772482N/A
3/31/20198191291977N/A
12/31/2018782123N/A83N/A
9/30/201867790N/A67N/A
6/30/201861678N/A90N/A
3/31/2018634110N/A137N/A
12/31/2017618103N/A127N/A
12/31/201643132N/A46N/A
12/31/201537922N/A42N/A
12/31/201429917N/A14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLAU3's forecast earnings growth (8.6% per year) is below the savings rate (11.2%).

Earnings vs Market: BLAU3's earnings (8.6% per year) are forecast to grow slower than the BR market (13.4% per year).

High Growth Earnings: BLAU3's earnings are forecast to grow, but not significantly.

Revenue vs Market: BLAU3's revenue (10.8% per year) is forecast to grow faster than the BR market (6.7% per year).

High Growth Revenue: BLAU3's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BLAU3's Return on Equity is forecast to be low in 3 years time (13.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/30 02:28
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blau Farmacêutica S.A. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários
Frederico MendesBradesco S.A. Corretora de Títulos e Valores Mobiliários
Samuel Campos AlvesBTG Pactual